--- title: "IGF-1 LR3 Dosage Guide [2026] | BodyHackGuide" url: https://www.bodyhackguide.co/guides/dosage/igf-1-lr3 description: "Complete IGF-1 LR3 dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Growth Hormone / IGF-1 Axis Preclinical # IGF-1 LR3 Dosage Guide: Protocols, Calculator & Safety Everything you need to know about IGF-1 LR3 dosing: protocols, safety, and where to buy. Dose Range 20-80 mcg per day Frequency Once daily, typically post-workout or in the morning Cycle Length 4–6 weeks maximum (to prevent receptor desensitization and hypoglycemia risk) Half-Life 20-30 hours (community/vendor estimate; no published human PK study of IGF-1 LR3) vs ~12 minutes for native IGF-1 ## Administration Routes Subcutaneous Intramuscular ### Quick Reconstitution Calculator Calculate syringe units instantly Syringe Draw 10.0 units 2500 mcg/ml · 0.100 ml draw Full Tool (https://www.bodyhackguide.co/tools/reconstitution) For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals. ## Dosing Protocols Beginner **Conservative beginner protocol:** - **Dose:** 20 mcg subcutaneous - **Frequency:** Once daily (either morning or post-workout) - **Timing:** With 30-40g fast-digesting carbohydrate within 30 minutes of injection - **Duration:** 4 weeks initial cycle with blood glucose monitoring **Do not skip the carbohydrate:** This is the most important rule. IGF-1 LR3's insulin-receptor cross-reactivity will drop blood glucose in the post-injection window. Users who inject fasted or combined with carb restriction have experienced hypoglycemic episodes requiring emergency intervention. Plan a carbohydrate-containing meal or shake to coincide with injection timing. **Reconstitution:** IGF-1 LR3 typically ships as 1 mg lyophilized powder. Reconstitute with acetic acid-stabilized solution or BAC water as supplier instructs (IGF-1 LR3 is unusual in often requiring dilute acetic acid rather than BAC water — verify with your source): - 1 mg + 1 mL = 1 mg/mL concentration - 20 mcg = 0.02 mL = **2 units** on U-100 insulin syringe (very small volume) Many users dilute further for ease of accurate measurement: - 1 mg + 2 mL = 500 mcg/mL - 20 mcg = 0.04 mL = 4 units **Timing considerations:** **Option A — Morning with breakfast:** Inject 20 mcg upon waking; consume high-carb breakfast within 30 min. Simplest and safest for beginners. **Option B — Post-workout with carb/protein shake:** Inject 20 mcg immediately post-training; consume carb + protein shake with 30-40g carbs within 20 min. Theoretically aligns IGF-1 signal with muscle damage window. **Option C — Pre-workout:** Not recommended for beginners — the hypoglycemia risk during training is significant. **First-dose precautions:** - Have simple carbohydrate (juice, glucose tabs) immediately available - Test blood glucose 30, 60, 90 min post-injection for the first 3-5 doses - Have a diabetes-literate friend or partner aware of what you're doing - If you develop shakiness, sweating, or confusion, immediately consume fast-digesting carbohydrate **Labs to run before starting:** - Baseline IGF-1 (to see where you are relative to age-adjusted norms) - Fasting insulin, fasting glucose, HbA1c - Comprehensive metabolic panel - CBC (baseline hematologic values) - Abdominal imaging is reasonable but not strictly required for short-term use **Who should not start:** - Users with any active or suspected malignancy - Strong family history of hormonally-responsive cancers - Uncontrolled diabetes - Hypoglycemia unawareness - Pediatric or adolescent users (use is highly inappropriate without specialist supervision) - Users who will not commit to glucose testing and carbohydrate management Standard **Standard intermediate protocol:** - **Dose:** 30-50 mcg subcutaneous - **Frequency:** Once daily - **Timing:** Post-workout on training days, morning with breakfast on rest days - **Cycle:** 4-6 weeks on / 2-4 weeks off **Why cycling:** IGF-1 LR3 is not cycled primarily for receptor desensitization (IGF1R does not desensitize rapidly at these doses) but rather to: - Limit cumulative peripheral tissue growth (gut, organs) - Limit cumulative cancer-promotion mechanistic exposure - Re-establish hypoglycemia tolerance **Dosing optimization:** **Site-targeted injection (local anabolic effect):** Some intermediate users inject IGF-1 LR3 directly into trained muscle groups immediately post-workout (bilateral 10-20 mcg into each side of the trained muscle, typically chest, back, or legs). Rationale: high local tissue concentration drives targeted hypertrophy. Evidence: primarily anecdotal; mechanistically plausible but not validated in controlled trials. Risks: increased hypoglycemia from pooled peripheral injection, increased injection site soreness/inflammation. **Systemic SC injection (standard):** Single SC injection in abdomen or thigh; drives systemic IGF-1 elevation affecting all IGF1R-expressing tissues. Simpler, safer than multiple IM injections. **Combination with exogenous insulin (not recommended):** Some advanced bodybuilders combine IGF-1 LR3 with rapid-acting insulin post-workout for maximum glucose disposal and nutrient partitioning. **This combination is extremely dangerous** — both agents independently drive hypoglycemia; combined, the risk of severe hypoglycemia requiring emergency intervention is high. If undertaken at all, only with continuous glucose monitoring and extensive carbohydrate protocols. **Most experienced practitioners specifically warn against this combination.** **Cycling protocol example:** - Weeks 1-4: 40 mcg SC daily, post-workout or morning - Weeks 5-8: Off (body composition assessment, labs) - Weeks 9-12: 50 mcg SC daily - Weeks 13-16: Off - Continue cycling pattern **Monitoring during cycle:** - Weekly fasting glucose (ensure no creeping elevation despite exogenous IGF-1) - Weekly fasting insulin - Week 4 and week 8: IGF-1, CBC, CMP - Quarterly: Abdominal palpation for any unusual masses; consider abdominal imaging annually Advanced **Advanced protocol — only for experienced users with full risk awareness:** The advanced IGF-1 LR3 user is generally combining it with other anabolic strategies in pursuit of maximum physique goals: **Anabolic intensification stack:** - **IGF-1 LR3:** 50-80 mcg SC post-workout, cycled 4-6 weeks on / 4 weeks off - **Testosterone replacement or cycle** (if applicable) - **GHRH + GHS combination** for pituitary GH axis support (sermorelin + ipamorelin, or CJC-1295 + ipamorelin) - **BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) + TB-500 (https://www.bodyhackguide.co/compound/tb-500)** for connective tissue and recovery - **Disciplined nutrition** with periworkout carbohydrate planning and overall caloric surplus **Why stack with GH axis support:** Endogenous GH/IGF-1 operates at physiologic levels with proper IGFBP regulation. Supplementing only exogenous LR3 bypasses the IGFBP system and produces all its effects through the unbound (free) IGF-1 mechanism. Some practitioners stack with GHRH/GHS compounds to also drive native IGF-1 production, arguing the combination gives you "best of both worlds." The counterargument is that you're stacking mechanisms and compounding the theoretical cancer-risk signal. **Cycling considerations for advanced use:** - Never exceed 8 consecutive weeks of IGF-1 LR3 use - Ensure 2-4 week washout between cycles minimum - Annual comprehensive physical with abdominal imaging - Semi-annual IGF-1 monitoring with trend analysis - Annual colonoscopy after age 40 (or earlier with family history) **Site-targeted protocols (experienced only):** Some bodybuilders inject small doses directly into trained muscle for local anabolic effect: - 10-20 mcg per side, bilateral injection, immediately post-training - High local tissue concentration drives targeted hypertrophy (theoretical) - Increases total IGF-1 exposure per session compared to single SC dose **Combinations to avoid at advanced level:** - **IGF-1 LR3 + exogenous insulin:** Compounded hypoglycemia risk; potentially lethal - **IGF-1 LR3 + mecasermin (Increlex):** Redundant; both are IGF1R agonists - **IGF-1 LR3 + sulfonylureas or meglitinides:** Severe hypoglycemia risk - **IGF-1 LR3 + aggressive carbohydrate restriction:** Dangerous - **IGF-1 LR3 in caloric deficit phases:** Inefficient — the anabolic signal is wasted if substrate is absent; the hypoglycemia risk is elevated without proper carb intake **Discontinuation triggers at any dose/level:** - Any new or changing skin lesion, lymphadenopathy, or palpable mass - Symptomatic abdominal distension or early satiety - Persistent HbA1c elevation despite appropriate carbohydrate management - New or worsened sleep apnea - Facial soft-tissue growth suggesting acromegalic changes - Any cardiovascular symptoms - Strong family history of cancer that was not previously known at start of use ## Weight-Based Dosing 0.5–1 mcg/kg per day. Do not exceed 100 mcg/day. ## Commonly Stacked With ### Mechanistically Synergistic **IGF-1 LR3 + Testosterone replacement (hypogonadal men) or cycle:** Classical anabolic synergy. Testosterone drives muscle protein synthesis through androgen receptor; IGF-1 LR3 through IGF1R/mTOR pathway. Additive hypertrophic effect well-established in bodybuilding community (not clinical trial data). **IGF-1 LR3 + GHRH + GHS (sermorelin/CJC-1295 + ipamorelin):** Drives endogenous GH/IGF-1 production in parallel with exogenous IGF-1 LR3. Pharmacologically redundant at the IGF-1 level but the GH axis also has direct effects on lipolysis and sleep architecture. Layering is popular but theoretically compounds cancer-risk signals. **IGF-1 LR3 + BPC-157 + TB-500:** Non-interfering mechanisms. IGF-1 LR3 drives muscle protein synthesis; BPC-157 and TB-500 support connective tissue and soft tissue remodeling under the increased training load. Appropriate combination. ### Context-Dependent **IGF-1 LR3 + MK-677 (https://www.bodyhackguide.co/compound/mk-677):** Both raise IGF-1 but through different mechanisms. MK-677 drives endogenous GH-mediated hepatic IGF-1 production (normal IGFBP binding); IGF-1 LR3 provides exogenous free IGF-1. Compounds the IGF-1 elevation significantly — cancer risk theoretical concern magnified. **IGF-1 LR3 + Creatine monohydrate:** Non-interfering; complementary. Creatine for phosphocreatine energy; IGF-1 LR3 for hypertrophy signaling. **IGF-1 LR3 + Beta-alanine, citrulline, other performance supplements:** Non-interfering. ### Avoid — Dangerous **IGF-1 LR3 + Exogenous insulin:** **Severe hypoglycemia risk.** Even in experienced users with continuous glucose monitoring, this combination has produced dangerous hypoglycemic episodes. Many advanced practitioners specifically warn against this despite its use in certain bodybuilding circles. **IGF-1 LR3 + Oral hypoglycemic medications (sulfonylureas, meglitinides):** Compounded hypoglycemia. **IGF-1 LR3 + Aggressive calorie restriction:** The anabolic signal is wasted without substrate; hypoglycemia risk is elevated without carb intake; no meaningful body composition benefit in deficit. **IGF-1 LR3 + Corticosteroids (high-dose prednisone, dexamethasone):** Pharmacodynamic antagonism — steroids promote muscle catabolism and oppose IGF-1 anabolic signaling. ### Mechanistically Redundant **IGF-1 LR3 + Mecasermin (Increlex):** Both are IGF1R agonists; mecasermin is native IGF-1, LR3 is the modified long-acting analog. Pick one. **IGF-1 LR3 + native IGF-1 / IGF-1 DES (1-3):** Redundant IGF1R activation. ### Related Compound Pages - MK-677 (https://www.bodyhackguide.co/compound/mk-677) — Oral GHS that drives endogenous IGF-1 elevation - CJC-1295 (https://www.bodyhackguide.co/compound/cjc-1295) — GHRH analog supporting native GH/IGF-1 axis - Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin) — Clean GHS-R1a agonist - Sermorelin (https://www.bodyhackguide.co/compound/sermorelin) — Pulsatile GHRH synergy - Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin) — FDA-approved GHRH analog - BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) — Connective tissue support partner - TB-500 (https://www.bodyhackguide.co/compound/tb-500) — Soft tissue remodeling partner - MOTS-c (https://www.bodyhackguide.co/compound/mots-c) — Mitochondrial peptide for metabolic health - NAD+ (https://www.bodyhackguide.co/compound/nad) — Mitochondrial cofactor ## Side Effects & Safety \## Acute and Common - **Hypoglycemia** — The primary acute safety concern. Post-injection blood glucose drops can produce shakiness, sweating, confusion, palpitations, and in severe cases loss of consciousness. Mitigation: 30-40g of fast-digesting carbohydrate within 30 minutes of injection; avoid combining with insulin or aggressive carb restriction; test blood glucose during first weeks of dosing. - **Injection site reactions** — Mild erythema and transient itching at SC site. Site rotation minimizes. - **Mild hunger** — From insulin-receptor activation and blood glucose effects, not ghrelin pathway. Less pronounced than with GHRP compounds. - **Slight warmth or flushing** — Occasional, short-lived. ## Less Common (Early) - **Jaw/temporomandibular pain** — Reported by some users particularly in first weeks; possibly related to growth effects on facial muscles or connective tissue - **Mild facial puffiness** — Water retention and soft-tissue growth - **Localized muscle soreness** at injection site — Occasionally severe in users who inject intramuscularly (IM) rather than SC - **Transient fatigue** — Usually in association with early hypoglycemic episodes - **Headache** — Mild, usually responsive to hydration ## Dose-Dependent with Chronic Use - **Peripheral tissue growth / "IGF gut"** — Intestinal epithelial hypertrophy produces a distinctive abdominal distension at high cumulative doses. This is an IGF-1 receptor expression phenomenon — the gut lining is highly proliferative and IGF1R-positive, so chronic high-dose IGF-1 LR3 drives measurable gut tissue growth. Reversible with discontinuation but takes weeks to months to fully resolve. - **Organ enlargement** — Liver, spleen, kidneys all express IGF1R. Chronic high-dose use can produce organomegaly detectable on imaging. Most users never develop this at typical bodybuilding doses, but the risk scales with dose and duration. - **Cardiac hypertrophy** — Theoretical concern. The heart responds to IGF-1 signaling; prolonged supraphysiologic exposure could contribute to left ventricular hypertrophy. Generally not clinically significant at typical use patterns but warrants periodic echocardiographic monitoring in long-term users. - **Lymphoid tissue hypertrophy** — Tonsillar enlargement, adenoid hypertrophy, occasionally submandibular lymph node enlargement. Documented in mecasermin pediatric trials; likely applies to IGF-1 LR3 at sufficient dose/duration. ## Long-term Theoretical - **Cancer risk** — This is the most important theoretical concern. IGF-1 is a pro-mitogenic signal; virtually every malignancy overexpresses IGF1R; elevated IGF-1 is a risk factor for breast, prostate, and colon cancers in epidemiologic studies. **Sustained supraphysiologic IGF-1 LR3 signaling has mechanistic plausibility for cancer promotion in users with any pre-existing occult malignancy or strong predisposition.** No large-population longitudinal data exists to quantify this risk in performance-dose LR3 users specifically, but the mechanism is well-established and conservative dosing with periodic screening is warranted. - **Acromegalic changes** — Soft tissue growth effects (enlarged hands/feet, facial bone remodeling) with very chronic high-dose use approaching acromegaly-like patterns. More common in exogenous HGH abuse but possible with sustained IGF-1 LR3. - **Diabetes risk** — Chronic insulin-receptor cross-activation could theoretically contribute to beta-cell exhaustion or insulin resistance patterns over very long timescales. ## Serious but Rare - **Severe hypoglycemia with loss of consciousness** — Usually preventable with appropriate carbohydrate management - **Symptomatic organomegaly** — Abdominal fullness, early satiety, or imaging abnormalities - **Unexpected new growth of pre-existing moles or tumors** — Immediate discontinuation and oncology evaluation ## Signs You Need to Stop - Any unexplained new or changing mass, lymphadenopathy, or pigmented lesion - Symptomatic abdominal distension or early satiety (suggesting gut/organ growth) - Persistent fasting glucose or HbA1c elevation - New chest pain, shortness of breath, or cardiovascular symptoms - Any signs of organomegaly on physical exam or imaging - Disproportionate lymphoid tissue enlargement (large tonsils, adenoids, or nodes) Contraindications IGF-1 LR3 is contraindicated or requires strict caution in: **Absolute contraindications:** - **Active malignancy, any type** — IGF-1 is a pro-mitogenic signal; IGF1R is expressed on virtually all cancer cells; supraphysiologic IGF-1 exposure in the presence of malignant cells has mechanistic cancer-promotion risk - **Strong family history of breast, prostate, colon, or other hormonally-responsive cancers** — elevated IGF-1 is an epidemiologic risk factor for these cancers - **Active proliferative retinopathy** — IGF-1 drives retinal neovascularization - **Pregnancy and lactation** — no safety data; theoretical fetal growth effects - **Pediatric or adolescent use** without specialist supervision — growth plate and organ development concerns - **Hypoglycemia unawareness or severe hypoglycemic episodes in history** — acute safety risk is unacceptable - **Known hypersensitivity** to IGF-1 LR3 or IGF-1 analogs **Strong relative cautions:** - **Diabetes mellitus** (any type) — hypoglycemia risk is significantly elevated and the condition itself involves disrupted IGF-1/insulin signaling - **Prior history of any cancer, even if treated and disease-free** — specialist supervision required if used at all - **Active or treated pituitary adenoma** — IGF-1 axis disruption concerns - **Organomegaly (hepatomegaly, splenomegaly)** — will worsen - **Active intestinal disease (Crohn's, ulcerative colitis, severe diverticular disease)** — gut growth effects may worsen symptoms - **Severe cardiovascular disease** — cardiac hypertrophy concerns - **Sleep apnea (untreated)** — soft-tissue growth may worsen airway obstruction **Relative cautions (monitor closely):** - Borderline glucose tolerance or HbA1c - Any history of benign tumor/adenoma (pituitary, adrenal, parathyroid) - Strong family history of colon polyps — colonoscopy surveillance essential - Users on immunosuppressants — theoretical concern about IGF-1 effects on cancer surveillance - Users with low-grade chronic inflammation or elevated hs-CRP — IGF-1 may modulate inflammation in complex ways - Users with prior skin cancer (even non-melanoma) — dermatology surveillance required **Drug interactions (dangerous):** - **Insulin (exogenous):** Compounded hypoglycemia; potentially life-threatening combination - **Sulfonylureas (glipizide, glyburide):** Compounded hypoglycemia - **Meglitinides (repaglinide):** Compounded hypoglycemia - **Mecasermin (Increlex):** Redundant; both IGF1R agonists; excessive IGF1R activation **Drug interactions (manage):** - **Corticosteroids (high-dose prednisone, dexamethasone):** Pharmacodynamic antagonism - **Aromatase inhibitors (letrozole, anastrozole):** May modify IGF-1 signaling indirectly - **Statins:** Some evidence of IGF-1 effects modulation - **Thyroid hormone:** Thyroid status affects IGF-1 receptor sensitivity **Discontinuation triggers (immediate):** - Any new or growing skin lesion, mass, or lymphadenopathy - Unexplained weight loss - Symptomatic abdominal distension, early satiety, or imaging abnormality - Persistent fasting glucose >110 mg/dL despite appropriate carb management - New chest pain, shortness of breath, or other cardiovascular symptoms - Facial or extremity changes suggesting acromegalic growth - Any severe hypoglycemic episode despite appropriate carb intake - Strong family cancer history revealed after starting use Check interactions with the Interaction Checker → (https://www.bodyhackguide.co/tools/interaction-checker) ## Additional Notes ### Standard Dosing Reference | User Tier | Daily Dose | Route | Cycle | | --- | --- | --- | --- | | Beginner | 20 mcg | SC | 4 weeks on / 4 weeks off | | Intermediate | 30-50 mcg | SC | 4-6 weeks on / 2-4 weeks off | | Advanced | 50-80 mcg | SC | 4-6 weeks on / 4 weeks off | | Site-targeted (advanced) | 10-20 mcg/side | IM into trained muscle | Per workout | ### Critical Rules 1. **Always dose with carbohydrate** — 30-40g fast-digesting carb within 30 min of injection to prevent hypoglycemia 2. **Never combine with exogenous insulin** — severe hypoglycemia risk 3. **Never dose fasted** — insulin-receptor cross-reactivity will drop blood glucose 4. **Cycle strictly** — 4-6 weeks on maximum, with 2-4 week washouts 5. **Monitor cancer-risk signals** — baseline labs, abdominal imaging if long-term use, regular physical exams 6. **Subcutaneous route for systemic use** — IM reserved for experienced users doing site-targeted protocols ### Concentration and Volume Standard 1 mg vial + 1 mL acetic acid solution = 1 mg/mL: - 20 mcg = 0.02 mL = **2 units** on U-100 insulin syringe (very small) - 40 mcg = 0.04 mL = **4 units** - 60 mcg = 0.06 mL = **6 units** - 80 mcg = 0.08 mL = **8 units** Many users prefer higher-volume dilutions for measurement accuracy: ### Monitoring (Critical for IGF-1 LR3) **Baseline (essential):** - IGF-1 level - Fasting insulin, fasting glucose, HbA1c - Comprehensive metabolic panel (liver, kidney function) - CBC with differential - Prostate-specific antigen (PSA) if male over 40 - Physical exam including breast/chest exam, abdominal palpation, testicular exam - Abdominal imaging (ultrasound or MRI) is reasonable but not strictly required **During cycle:** - Weekly fasting glucose (first cycle) - Monthly fasting insulin, HbA1c - Week 4: IGF-1, CBC, CMP **Periodic (ongoing long-term):** - Quarterly IGF-1 - Semi-annual fasting glucose, HbA1c, CMP - Annual comprehensive physical exam including abdominal imaging - Annual colonoscopy after age 40 (or earlier per family history) - Dermatologic full-body skin exam annually ### When Not to Dose - Fasted state - Post-prolonged cardiovascular exercise without carb replacement - With exogenous insulin (dangerous combination) - During acute illness with fever - If current HbA1c is elevated despite carb management - If any unexplained new mass or symptom has not been evaluated - During caloric deficit phases (wasted signal) ### Storage - Lyophilized: refrigerated 2-8°C, sealed, stable up to 2 years - Reconstituted: refrigerated 2-8°C, use within **30 days** - Never freeze - Protect from light Where to Buy IGF-1 LR3 Compare 5 listings across 5 vendors, from $49.99 https://www.bodyhackguide.co/compound/igf-1-lr3 ## Frequently Asked Questions What is the recommended IGF-1 LR3 dosage? The typical dose range for IGF-1 LR3 is 20-80 mcg per day. It is usually administered Once daily, typically post-workout or in the morning. Always start with the lowest effective dose. How often should I take IGF-1 LR3? Does IGF-1 LR3 need to be cycled? Yes, typical cycle length is 4–6 weeks maximum (to prevent receptor desensitization and hypoglycemia risk). What are IGF-1 LR3 side effects? Where can I buy IGF-1 LR3? Compare 5 listings from 5 vendors on our price comparison page, starting from $49.99. IGF-1 LR3 Full Profile Research data, mechanisms, and pricing https://www.bodyhackguide.co/compound/igf-1-lr3 Interaction Checker Check drug & compound interactions https://www.bodyhackguide.co/tools/interaction-checker ## Related Dosage Guides All Guides (https://www.bodyhackguide.co/guides) ### CJC-1295 (Mod GRF 1-29) Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295 ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295-dac ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295-with-dac ### GHRP-2 Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/ghrp-2 Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Article", "headline": "IGF-1 LR3 Dosage Guide [2026]", "description": "Complete IGF-1 LR3 dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026.", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the recommended IGF-1 LR3 dosage?", "acceptedAnswer": { "@type": "Answer", "text": "The typical dose range for IGF-1 LR3 is 20-80 mcg per day. It is usually administered Once daily, typically post-workout or in the morning. Always start with the lowest effective dose." } }, { "@type": "Question", "name": "How often should I take IGF-1 LR3?", "acceptedAnswer": { "@type": "Answer", "text": "Once daily, typically post-workout or in the morning" } }, { "@type": "Question", "name": "Does IGF-1 LR3 need to be cycled?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, typical cycle length is 4–6 weeks maximum (to prevent receptor desensitization and hypoglycemia risk)." } }, { "@type": "Question", "name": "What are IGF-1 LR3 side effects?", "acceptedAnswer": { "@type": "Answer", "text": "## Acute and Common\n\n- **Hypoglycemia** — The primary acute safety concern. Post-injection blood glucose drops can produce shakiness, sweating, confusion, palpitations, and in severe cases loss of consciousness. Mitigation: 30-40g of fast-digesting carbohydrate within 30 minutes of injection; avoid combining with insulin or aggressive carb restriction; test blood glucose during first weeks of dosing.\n- **Injection site reactions** — Mild erythema and transient itching at SC site. Site rotation minimizes.\n- **Mild hunger** — From insulin-receptor activation and blood glucose effects, not ghrelin pathway. Less pronounced than with GHRP compounds.\n- **Slight warmth or flushing** — Occasional, short-lived.\n\n## Less Common (Early)\n\n- **Jaw/temporomandibular pain** — Reported by some users particularly in first weeks; possibly related to growth effects on facial muscles or connective tissue\n- **Mild facial puffiness** — Water retention and soft-tissue growth\n- **Localized muscle soreness** at injection site — Occasionally severe in users who inject intramuscularly (IM) rather than SC\n- **Transient fatigue** — Usually in association with early hypoglycemic episodes\n- **Headache** — Mild, usually responsive to hydration\n\n## Dose-Dependent with Chronic Use\n\n- **Peripheral tissue growth / \"IGF gut\"** — Intestinal epithelial hypertrophy produces a distinctive abdominal distension at high cumulative doses. This is an IGF-1 receptor expression phenomenon — the gut lining is highly proliferative and IGF1R-positive, so chronic high-dose IGF-1 LR3 drives measurable gut tissue growth. Reversible with discontinuation but takes weeks to months to fully resolve.\n- **Organ enlargement** — Liver, spleen, kidneys all express IGF1R. Chronic high-dose use can produce organomegaly detectable on imaging. Most users never develop this at typical bodybuilding doses, but the risk scales with dose and duration.\n- **Cardiac hypertrophy** — Theoretical concern. The heart responds to IGF-1 signaling; prolonged supraphysiologic exposure could contribute to left ventricular hypertrophy. Generally not clinically significant at typical use patterns but warrants periodic echocardiographic monitoring in long-term users.\n- **Lymphoid tissue hypertrophy** — Tonsillar enlargement, adenoid hypertrophy, occasionally submandibular lymph node enlargement. Documented in mecasermin pediatric trials; likely applies to IGF-1 LR3 at sufficient dose/duration.\n\n## Long-term Theoretical\n\n- **Cancer risk** — This is the most important theoretical concern. IGF-1 is a pro-mitogenic signal; virtually every malignancy overexpresses IGF1R; elevated IGF-1 is a risk factor for breast, prostate, and colon cancers in epidemiologic studies. **Sustained supraphysiologic IGF-1 LR3 signaling has mechanistic plausibility for cancer promotion in users with any pre-existing occult malignancy or strong predisposition.** No large-population longitudinal data exists to quantify this risk in performance-dose LR3 users specifically, but the mechanism is well-established and conservative dosing with periodic screening is warranted.\n- **Acromegalic changes** — Soft tissue growth effects (enlarged hands/feet, facial bone remodeling) with very chronic high-dose use approaching acromegaly-like patterns. More common in exogenous HGH abuse but possible with sustained IGF-1 LR3.\n- **Diabetes risk** — Chronic insulin-receptor cross-activation could theoretically contribute to beta-cell exhaustion or insulin resistance patterns over very long timescales.\n\n## Serious but Rare\n\n- **Severe hypoglycemia with loss of consciousness** — Usually preventable with appropriate carbohydrate management\n- **Symptomatic organomegaly** — Abdominal fullness, early satiety, or imaging abnormalities\n- **Unexpected new growth of pre-existing moles or tumors** — Immediate discontinuation and oncology evaluation\n\n## Signs You Need to Stop\n\n- Any unexplained new or changing mass, lymphadenopathy, or pigmented lesion\n- Symptomatic abdominal distension or early satiety (suggesting gut/organ growth)\n- Persistent fasting glucose or HbA1c elevation\n- New chest pain, shortness of breath, or cardiovascular symptoms\n- Any signs of organomegaly on physical exam or imaging\n- Disproportionate lymphoid tissue enlargement (large tonsils, adenoids, or nodes)" } }, { "@type": "Question", "name": "Where can I buy IGF-1 LR3?", "acceptedAnswer": { "@type": "Answer", "text": "Compare 5 listings from 5 vendors on our price comparison page, starting from $49.99." } } ] }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 3, "name": "Dosage Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 4, "name": "IGF-1 LR3 Dosage", "item": "https://www.bodyhackguide.co/guides/dosage/igf-1-lr3" } ] } ] ```